Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KDM4A | O75164 | 1/20 | 0.32 |
| ▸ | NQO2 | P16083 | 1/20 | 0.31 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.30 |
| ▸ | KDM5A | P29375 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19101154 | 0.82 | MLYCD (0.35) | RAB9A | |
| SCHEMBL7784055 | 0.79 | ALDH1A1 (0.42) | ALDH1A1HPGDSMN1; SMN2KDM4ARAB9A | |
| SCHEMBL22372230 | 0.76 | SCN9A (0.36) | — | |
| Hydrogen Sulfide SCHEMBL11219494 | 0.73 | — | — | |
| SCHEMBL2210189 | 0.72 | — | — | |
| SCHEMBL9426831 | 0.71 | — | — | |
| SCHEMBL28905564 | 0.71 | — | — | |
| SCHEMBL30149273 | 0.71 | KDM4E (0.36) | ALDH1A1KDM4AKDM5A | |
| SCHEMBL30522334 | 0.71 | — | — | |
| Ammonia Solution, Strong SCHEMBL28124824 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198309-B2 | N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl)hetaryl arylsulfonamides | CHEMOCENTRYX, INC. (US) | 2012-06-12 | — | — | US | claimed |
| US-4281007-A | A CLAY AND AN ALIPHATIC POLYOL | GULF OIL CORPORATION (US) | 1981-07-28 | — | — | US | claimed |
| US-20250129063-A1 | BENZOTHIAZOLE COMPOUNDS AS VHL LIGANDS | GENENTECH, INC. (US) | 2025-04-24 | — | — | US | disclosed |
| EP-4522270-A1 | BENZOTHIAZOLE COMPOUNDS AS VHL LIGANDS | Genentech Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| WO-2023220237-A1 | BENZOTHIAZOLE COMPOUNDS AS VHL LIGANDS | GENENTECH, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-20230098016-A1 | COMPOSITIONS AND METHODS FOR INHIBITING PHENYL TRIAZOLE MLL1-WDR5 PROTEIN-PROTEIN INTERACTION | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2023-03-30 | — | — | US | disclosed |
| CN-109734674-B | Aniline WDR5 protein-protein interaction inhibitor and preparation method and application thereof | 中国药科大学 | 2022-08-26 | — | — | CN | disclosed |
| US-20220152027-A1 | ANILINE-BASED WDR5 PROTEIN-PROTEIN INTERACTION INHIBITOR, AND PREPARATION METHOD AND USE THEREOF | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2022-05-19 | — | — | US | disclosed |
| EP-3932910-A1 | ANILINE WDR5 PROTEIN-PROTEIN INTERACTION INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | China Pharmaceutical University (CN) | 2022-01-05 | — | — | EP | disclosed |
| US-20210139466-A1 | COMPOSITIONS AND METHODS FOR INHIBITING PHENYL TRIAZOLE MLL1-WDR5 PROTEIN-PROTEIN INTERACTION | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2021-05-13 | — | — | US | disclosed |
| CN-112368268-A | Phenyl-bis-triazole MLL1-WDR5 protein-protein interaction inhibitor | 中国药科大学 | 2021-02-12 | — | — | CN | disclosed |
| US-20080125409-A1 | 1,5-Diheterocycle-1H-Triazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-05-29 | — | — | US | disclosed |
| US-20080064682-A1 | Pyrazole Derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-03-13 | — | — | US | disclosed |
| US-20070254881-A1 | Pyrazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-11-01 | — | — | US | disclosed |
| EP-1803719-A1 | 1,5-DIHETEROCYCLE-1H-TRIAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-07-04 | — | — | EP | disclosed |
| EP-1785418-A1 | PYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-05-16 | — | — | EP | disclosed |
| EP-1762568-A1 | PYRAZOLE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-14 | — | — | EP | disclosed |
| US-4281007-A | A CLAY AND AN ALIPHATIC POLYOL | GULF OIL CORPORATION (US) | 1981-07-28 | — | — | US | disclosed |
| US-4281007-A | A CLAY AND AN ALIPHATIC POLYOL | GULF OIL CORPORATION (US) | 1981-07-28 | — | — | US | disclosed |
| US-4281007-A | A CLAY AND AN ALIPHATIC POLYOL | GULF OIL CORPORATION (US) | 1981-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125409-A1 | 1,5-Diheterocycle-1H-Triazole Derivative | PTGS1, PTGER1, TBXA2R | ALDH1A1 185/4885HPGD 80/4885SMN1; SMN2 3713/4885 |
| US-20070254881-A1 | Pyrazole Derivative | PTGER1, PTGS1, PTGER2 | ALDH1A1 111/4885HPGD 39/4885SMN1; SMN2 3490/4885 |
| US-20210139466-A1 | COMPOSITIONS AND METHODS FOR INHIBITING PHENYL TRIAZOLE MLL1-WDR5 PROTEIN-PROTEIN INTERACTION | WDR5, MLLT1, WDR1 | ALDH1A1 3515/4885HPGD 4068/4885SMN1; SMN2 2957/4885 |
| US-20230098016-A1 | COMPOSITIONS AND METHODS FOR INHIBITING PHENYL TRIAZOLE MLL1-WDR5 PROTEIN-PROTEIN INTERACTION | WDR5, MLLT1, WDR1 | ALDH1A1 3515/4885HPGD 4068/4885SMN1; SMN2 2957/4885 |
| US-20080064682-A1 | Pyrazole Derivatives | NAT1, AR, CBR3 | ALDH1A1 248/4885HPGD 1996/4885SMN1; SMN2 3660/4885 |
| US-20250129063-A1 | BENZOTHIAZOLE COMPOUNDS AS VHL LIGANDS | VHL, BRCA1, GLS | ALDH1A1 2210/4885HPGD 2074/4885SMN1; SMN2 1771/4885 |
| US-20220152027-A1 | ANILINE-BASED WDR5 PROTEIN-PROTEIN INTERACTION INHIBITOR, AND PREPARATION METHOD AND USE THEREOF | MLLT1, WDR77, MLLT3 | ALDH1A1 2270/4885HPGD 4112/4885SMN1; SMN2 2626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.